摘要
胰岛素是治疗糖尿病的重要药物,皮下注射是临床上胰岛素的传统给药方式。为模拟正常生理状态下的胰岛素分泌曲线,达到良好的血糖控制效果,各种速、中、长效型的胰岛素类似物注射剂被联合使用。但长期的皮下注射常伴随着严重的不良反应。为提高患者的用药顺应性,胰岛素的非注射递药系统在近几年得到广泛的研究。本文总结了胰岛素给药新剂型,包括口服、经鼻、经肺、经皮、可注射原位凝胶和闭环给药的研发现状,并汇总了新剂型开发过程中影响胰岛素生物利用度和降血糖效果的因素。
Insulin is an important antidiabetic drug, subcutaneous injection is its traditional administration route in clinic. To simulate the curve of insulin secretion under normal physiological conditions and achieve good glycemic control, the rapid-, medium- and long-acting insulin analogues are usually used in combination. But long- term subcutaneous injection usually brings patients severe side effects. In order to improve patient compliance, novel non-injection administrations of insulin have been widely studied in recent years. Oral, nasal, pulmonary, transdermal, injectable in-situ gel and closed-loop delivery systems of insulin are reviewed in this paper. And the factors affecting insulin bioavailability and hypoglycemic effects in the process of developing novel delivery systems are also summarized.
出处
《中国医药工业杂志》
CAS
CSCD
北大核心
2015年第11期1236-1244,共9页
Chinese Journal of Pharmaceuticals
基金
"重大新药创制"科技重大专项--上药集团研发体系产学研技术联盟建设(2010ZX09401-404)
关键词
胰岛素
给药系统
口服
经鼻
经肺
经皮
可注射原位凝胶
闭环
综述
insulin
drug delivery system
oral
nasal
pulmonary
transdermal
injectable in-situ gel
closed-loop
review
